艾伯维宣布Tepkinly®(epcoritamab)联合来那度胺和利妥昔单抗获欧盟委员会批准用于治疗复发或难治性滤泡性淋巴瘤

美股速递
18 hours ago

艾伯维公司宣布,其药物Tepkinly®(epcoritamab)与来那度胺及利妥昔单抗的联合治疗方案,已获得欧盟委员会批准,用于治疗复发或难治性滤泡性淋巴瘤患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10